Characterization of epidemiological distribution and outcome of COVID-19 in patients with hereditary hemorrhagic telangiectasia: a nationwide retrospective multi-centre study during first wave in Italy

Table 4 Clinical characteristics of the 9 patients with hereditary hemorrhagic telangiectasia (HHT) with ascertained SarsCov-2 infection

ID	Gender	Age	Epistaxis before SarsCov-2 infection	Epistaxis profile during infection	Visceral involvement (AVMs)	Hb deficit level	Covid-19 symptoms/manifestations	Non-HHT co-morbidities
4	F	41	Yes	Worsening	No	Mild	GOS	Osteoporosis, Autoimmune Thyroiditis
20	M	46	Yes	Unchanged	No	Mild	Asymptomatic	Hypert., Hemodialysis, Chronic Kidney Disease
22	M	44	Yes	Unchanged	No	Intermediate	Pn, F, C,T, R, D, ST, GOS^a
24	M	57	Yes	Unchanged	No		Pn, F, C, R^b
34	F	38	Yes	Worsening	No		F, R, M,T, ST
39	F	35	Yes	Worsening	P, H	Mild	F, H, M,T, D	Asthma
49	M	41	Yes	Unchanged	No	Mild	F, C,H, M,T,GOS
66	M	49	Yes	Unchanged	No		Pn, F, R	Hypert
119	M	65	Yes	Unchanged	P, H, GI	Mild	Pn, F, C, T

Visceral Involvement: Organ displaying HHT-related Arterio-Venous Malformations (AVMs). P pulmonary arterio-venous malformations, H hepatic arterio-venous malformations, GI gastrointestinal arterio-venous malformations, Pn pneumonia, F fever, C coughing, H headache, R respiratory dyspnea, M muscular pain, T sense of tiredness/fatigue, D diarrhoea, ST sore throat, GOS gustative/olfactory sensory impairment. Hb level: Mild (Hb > 12 gr/dl), Intermediate (10–12 gr/dl), Severe 7–10 gr/dl), Very Severe (< 7 gr/dl)
^aNeeded Hospitalization and Intensive care (Invasive Ventilation)
^bNeeded Hospitalization and Intensive care (Non-Invasive Ventilation)

ISSN: 1750-1172